A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
NCT01122875
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
14
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Myeloma
Interventions
DRUG:
MFGR1877S
Sponsor
Genentech, Inc.